OR WAIT null SECS
Advancements in personalized medicine and other innovations are transforming the way dosage forms are viewed.
This study aimed to develop a taste-masked drug resin complex using the ion exchange resin Kyron T-114.
Novel genetic engineering technologies are transforming the design and manufacture of bispecific antibodies, which are emerging as a promising new class of biologics.
November 01, 2010
The author reviews key considerations for formulating powders for use in inhalers. This article is part of a special Drug Delivery issue.
A review on the current status of long-acting injectables, including commercially marketed products. This article is part of a special Drug Delivery issue.
The authors describe an alternative approach to compressing and coating minitablets for use in a sustained-release, solid oral-dosage form. This article is part of a special Drug Delivery issue.
The author outlines how to choose carriers and capsule shells according to dosage requirements and intended use. This article is part of a special Drug Delivery issue.
The author reviews advances in technology that may soon allow transdermal delivery of two of the fastest growing drug classes on the pharmaceutical market. This article is part of a special Drug Delivery issue.
October 31, 2010
Although there are no regulatory requirements or established pharmacopoeial techniques for the dissolution testing of inhaled drugs, such testing can potentially open up the opportunity to tailor formulation properties.
October 19, 2010
Pfizer announced this his week that it had entered into a strategic global agreement for the worldwide commercialization with the Indian biotechnology company Biocon (Bangalore) for biosimilar versions of insulin and insulin analog products (e.g., recombinant human insulin, glargine, aspart, and lispro).
October 07, 2010
FDA to Hold Public Hearing on Biosimilars Legislation, And More.
October 02, 2010
A recently released industry guide outlines a science- and risk-based approach to control the risk of cross-contamination.
Drugmakers hatch new manufacturing paradigms in the wake of the 2009 H1N1 influenza pandemic.